Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Ameliorative Effects of Atorvastatin on Bleomycin-Induced Pulmonary Fibrosis in Rats

Ali Asghar Hemmeti 1 , 2 , Mohammad Rahim Zerafatfard 1 , Mehdi Goudarzi 1 , Mohammad Javad Khodayar 1 , 3 , * , Anahita Rezaie 4 , Mohammad Reza Rashidi Nooshabadi 1 and Milad Kiani 1
Authors Information
1 Department of Pharmacology and Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Physiology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
3 Toxicology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
4 Department of Pathobiology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: November 2016, 11 (4); e13370
  • Published Online: September 17, 2016
  • Article Type: Research Article
  • Received: September 9, 2013
  • Revised: May 24, 2016
  • Accepted: August 17, 2016
  • DOI: 10.17795/jjnpp-13370

To Cite: Hemmeti A A, Zerafatfard M R, Goudarzi M, Khodayar M J, Rezaie A, et al. Ameliorative Effects of Atorvastatin on Bleomycin-Induced Pulmonary Fibrosis in Rats, Jundishapur J Nat Pharm Prod. 2016 ; 11(4):e13370. doi: 10.17795/jjnpp-13370.

Abstract
Copyright © 2016, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012; 21(126): 355-61[DOI][PubMed]
  • 2. Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet. 2012; 380(9842): 680-8[DOI][PubMed]
  • 3. Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol. 2014; 9: 157-79[DOI][PubMed]
  • 4. Grande NR, Peao MN, de Sa C. M. , Aguas AP. Lung fibrosis induced by bleomycin: structural changes and overview of recent advances. Scanning Microsc. 1998; 12(3): 487-94
  • 5. B. Moore B , Lawson WE, Oury TD, Sisson TH, Raghavendran K, Hogaboam CM. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013; 49(2): 167-79[DOI][PubMed]
  • 6. Javadi I, Rashidi Nooshabadi M, Goudarzi M, Roudbari R. Protective Effects of Celery (Apium graveloens) Seed Extract on Bleomycin-Induced Pulmonary Fibrosis in Rats. J Bbol Uni Med Sci. 2015; 17(1): 70-6
  • 7. Ebrahimi Naghani E, Javadi I, Rashidinooshabadi M, Godarzi M, Houshmand G. Protective Effects of Hydroalcoholic Extract of Hypericum Perforatum Against Bleomycin-Induced Pulmonary Fibrosis in Rats. J Babol Uni Med Sci. 2016; 18(1): 44-51
  • 8. Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014; 88: 3-11[DOI][PubMed]
  • 9. Atorvastatin F. Statins: HMG-CoA Reductase Inhibitors. 2013;
  • 10. Node K, Liao JK. Pleiotropic effects of HMG-CoA reductase. HMG-CoA Reductase Inhibit. 2012; : 81
  • 11. Murrow JR, Sher S, Ali S, Uphoff I, Patel R, Porkert M, et al. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. J Clin Lipidol. 2012; 6(1): 42-9[DOI][PubMed]
  • 12. Sozer V. Ameliorative effect of statin therapy on oxidative damage in heart tissue of hypercholesterolemic rabbits. Fundam Clin Pharmacol. 2015; 29(6): 558-66[DOI][PubMed]
  • 13. Margaritis M, Channon KM, Antoniades C. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxid Redox Signal. 2014; 20(8): 1198-215[DOI][PubMed]
  • 14. Subramanian S, Emami H, Vucic E, Singh P, Vijayakumar J, Fifer KM, et al. High-dose atorvastatin reduces periodontal inflammation: a novel pleiotropic effect of statins. J Am Coll Cardiol. 2013; 62(25): 2382-91[DOI][PubMed]
  • 15. Ortego M, Bustos C, Hernandez-Presa MA, Tu-on J, Diaz C, Hernandez G. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999; 147(2): 253-61[DOI]
  • 16. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001; 59(3): 646-54[PubMed]
  • 17. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2001; 154(1): 87-96[PubMed]
  • 18. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003; 108(4): 426-31[DOI][PubMed]
  • 19. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. 1998; 138(2): 271-80[DOI]
  • 20. Zhu B, Ma AQ, Yang L, Dang XM. Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway. Int J Mol Sci. 2013; 14(12): 24476-91[DOI][PubMed]
  • 21. Khodayar MJ, Kiani M, Hemmati AA, Rezaie A, Zerafatfard MR, Rashidi Nooshabadi MR, et al. The preventive effect of atorvastatin on paraquat-induced pulmonary fibrosis in the rats. Adv Pharm Bull. 2014; 4(4): 345-9[DOI][PubMed]
  • 22. Hemmati AA, Mikaili P, Khodayar MJ, Ghafurian M, Rashidi I. The protective effect of Cetirizine against Bleomycine induced pulmonary fibrosis in rats. Pak J Med Sci. 2008; 24(6): 813-20
  • 23. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988; 41(4): 467-70[PubMed]
  • 24. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem. 1996; 29(3): 225-9[PubMed]
  • 25. Javad-Mousavi SA, Hemmati AA, Mehrzadi S, Hosseinzadeh A, Houshmand G, Rashidi Nooshabadi MR, et al. Protective effect of Berberis vulgaris fruit extract against Paraquat-induced pulmonary fibrosis in rats. Biomed Pharmacother. 2016; 81: 329-36[DOI][PubMed]
  • 26. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978; 52: 302-10[PubMed]
  • 27. Kiener PA, Davis PM, Murray JL, Youssef S, Rankin BM, Kowala M. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol. 2001; 1(1): 105-18[DOI]
  • 28. Singh U, Devaraj S, Jialal I, Siegel D. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol. 2008; 102(3): 321-5[DOI][PubMed]
  • 29. Costabel U, King TE. International consensus statement on idiopathic pulmonary fibrosis. Eur Respir J. 2001; 17(2): 163-7[PubMed]
  • 30. Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol. 1991; 65(2): 81-94[PubMed]
  • 31. Sogut S, Ozyurt H, Armutcu F, Kart L, Iraz M, Akyol O, et al. Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats. Eur J Pharmacol. 2004; 494(2-3): 213-20[DOI][PubMed]
  • 32. Balakumar P, Mahadevan N. Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? Br J Pharmacol. 2012; 165(2): 373-9[DOI][PubMed]
  • 33. Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res. 2006; 98(3): 361-9[DOI][PubMed]
  • 34. Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther. 2006; 110(3): 371-85[DOI][PubMed]
  • 35. Mansure J, Nassim R, Kassouf W. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target in cancer. Cellular Genetic Practices Translational Med. 2011; 8(7): 169-95
  • 36. Zheng X, Cui XX, Avila GE, Huang MT, Liu Y, Patel J, et al. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res. 2007; 13(18 Pt 1): 5480-7[DOI][PubMed]
  • 37. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax. 2006; 61(8): 729-34[DOI][PubMed]
  • 38. Costa S, Reina-Couto M, Albino-Teixeira A, Sousa T. Statins and oxidative stress in chronic heart failure. Revista portuguesa de cardiologia: orgao oficial da Sociedade Portuguesa de Cardiologia. Portuguese J Cardiol. 2016;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments